1. Home
  2. ASBP
  3. ASBP News

Latest Aspire Biopharma Holdings Inc. Common Stock (ASBP) News on April 19, 2025

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
ASBP

GlobeNewswire

3 days ago

Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
ASBP

ACCESS Newswire

5 days ago

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
ASBP

ACCESS Newswire

8 days ago

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
ASBP

ACCESS Newswire

10 days ago

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
ASBP

ACCESS Newswire

a month ago

Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
ASBP

ACCESS Newswire

a month ago

Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation
ASBP

Newsfile

a month ago

An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
ASBP

ACCESS Newswire

2 months ago

Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
ASBP

ACCESS Newswire

2 months ago

Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
ASBP

ACCESS Newswire

2 months ago

Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq
ASBP

ACCESS Newswire

2 months ago

Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq

Share on Social Networks: